Products - Breast cancer | Topic | NICE

Showing 111 products

Date | Title

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 July 2024
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
9 May 2024
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 February 2024
Early and locally advanced breast cancer: diagnosis and management (NG101)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
16 January 2024
Published:
18 July 2018
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
14 November 2023
Published:
25 June 2013
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
23 June 2015
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2022
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
5 October 2022
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 August 2022
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (TA810)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 July 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2022
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 September 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 July 2020
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 June 2020
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2020
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2019
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2018
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2018
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 November 2017
Published:
19 July 2017
Advanced breast cancer: diagnosis and treatment (CG81)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
16 August 2017
Published:
23 February 2009
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
7 August 2013
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 October 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 January 2012
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2011
Image-guided radiofrequency excision biopsy of breast lesions (IPG308)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 July 2009
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 April 2009
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 July 2008
Laparoscopic mobilisation of the greater omentum for breast reconstruction (IPG253)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 February 2008
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2007
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
14 December 2005
Interstitial laser therapy for breast cancer (IPG89)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 September 2004
Improving outcomes in breast cancer (CSG1)
Product type:
Guidance
Programme:
Cancer service guideline
Published:
28 August 2002
Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 March 2002
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 October 2022
Contrast-enhanced spectral mammography for breast cancer (MIB304)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
30 August 2022
Artificial intelligence in mammography (MIB242)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
5 January 2021
Magseed for locating impalpable breast cancer lesions (MIB236)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
17 November 2020
AlignRT in breast cancer radiotherapy (MIB157)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
24 August 2018
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 January 2018
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 July 2017
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
24 August 2016
ATEC system for vacuum-assisted breast biopsy (MIB43)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
10 November 2015
Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
16 December 2014
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Product type:
Advice
Programme:
Evidence summary
Published:
13 March 2013
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Breast cancer (QS12)
Product type:
Quality standard
Last updated:
16 June 2016
Published:
28 September 2011
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2025
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 March 2025
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
31 March 2025
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 June 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Image-guided high intensity focused ultrasound to treat breast cancer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Breast cancer guidelines
Status:
In development
Programme:
NICE Hub
Expected publication date:
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer ID6425
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Magtrace/Sentimag MT599 (MIB263)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Signatera molecular residual disease assay (MT741)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Advanced breast cancer: diagnosis and management (Partial update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years TS ID 12116
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy ID6509
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours ID6511
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Artificial intelligence technologies for mammography: early value assessment
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC